The NIH-led study that gave the world the first positive, randomized remdesivir result has come back with a second one, showing that, when combined with remdesivir, an Eli Lilly molecule can slightly improve to time to recovery over remdesivir alone.
The ACTT-2 trial, a follow-up that began after the remdesivir section was completed, enrolled over 1,000 hospitalized Covid-19 patients and found that those given the antiviral remdesivir plus the Eli Lilly JAK inhibitor baricitinib recovered a median of “approximately one day” sooner than those given remdesivir alone. Similar to the IL-6 inhibitors from Regeneron and Roche — which failed in Phase III trials — baricitinib was designed to tamp down the overactive immune response seen in the later stages of Covid-19.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 89,900+ biopharma pros reading Endpoints daily — and it's free.
"heavy" - Google News
September 09, 2020 at 02:00PM
https://ift.tt/3c4ifiA
Merck's Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa - Endpoints News
"heavy" - Google News
https://ift.tt/35FbxvS
https://ift.tt/3c3RoCk
heavy
Bagikan Berita Ini
0 Response to "Merck's Roger Perlmutter steps up with a cash-heavy, $4.5 billion deal to ally with Seattle Genetics on an under-the-radar ADC and newly-approved Tukysa - Endpoints News"
Post a Comment